CYTK
NGSCytokinetics Incorporated
Healthcare•Biotechnology
Watchlists:
Last updated: Monday 21st July 2025
37.23
-1.66 (-4.27%)
Prev Close:38.89
Open:39.17
Bid:36.92
Ask:37.5
52 Week Range
29.3161.38
Volume:1,741,817
Mkt Cap:4,539 M
40
MarketXLS Rank ®
Hold
Price Target
$42.81
+15.0%
Financial Statements
CYTK - Income Statement (Annual)
| Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Depreciation And Amortization | 10 M | 12 M | 6 M | 2 M | 2 M | 1 M | -1 M | -2 M | -700000.0 | -600000.0 |
| Gain On Sale Of Security | 1 M | |||||||||
| General And Administrative Expense | 215 M | 174 M | 178 M | 97 M | 53 M | 40 M | 31 M | 36 M | 28 M | 20 M |
| Gross Profit Margin (profit Margin After CGS) | -321 M | 8 M | -146 M | -90 M | -41 M | 27 M | 32 M | 13 M | 106 M | 29 M |
| Interest Expense Non Operating | 38 M | 28 M | 51 M | 29 M | 39 M | 7 M | 4 M | 3 M | 3 M | 268000.0 |
| Interest Expense Operating | -2 M | -94000.0 | ||||||||
| Misc Other Special Charges | 52 M | 28 M | 11 M | 331000.0 | 5 M | 5 M | ||||
| Net Income (loss) | -590 M | -526 M | -389 M | -215 M | -127 M | -122 M | -106 M | -128 M | 16 M | -38 M |
| Net Income Common Stockholders | -590 M | -526 M | -389 M | -215 M | -127 M | -122 M | -106 M | -128 M | 16 M | -38 M |
| Net Income Continuous Operations | -590 M | -526 M | -389 M | -215 M | -127 M | -122 M | -106 M | -128 M | 16 M | -38 M |
| Net Income From Other Gains Losses | -57 M | -13 M | -23 M | -21 M | -18 M | -14 M | ||||
| Net Non Operating Interest Income Expense | -38 M | -28 M | 40 M | -16 M | -16 M | -7 M | 394000.0 | -414000.0 | -2 M | -94000.0 |
| Non Recurring Operation Expense | -4 M | |||||||||
| Normalized Income | -516 M | |||||||||
| Operating Income | -536 M | -496 M | -324 M | -186 M | -94 M | -99 M | -89 M | -113 M | 19 M | -37 M |
| Operating Income Before Depreciation (EBITDA) | -575 M | -502 M | -332 M | -184 M | -87 M | -96 M | -85 M | -109 M | 18 M | -37 M |
| Operating Expense | 555 M | 504 M | 178 M | 257 M | 150 M | 126 M | -120 M | -127 M | -88 M | -66 M |
| Other Gand A | 215 M | 174 M | 178 M | 97 M | 53 M | 40 M | 31 M | 36 M | 28 M | 20 M |
| Other Impairment Of Capital Assets | 3 M | |||||||||
| Other Operating Expenses | -6 M | -7 M | -4 M | -802000.0 | -603000.0 | -447000.0 | -110000.0 | -2 M | -845000.0 | -441000.0 |
| Rent And Landing Fees | 31 M | 36 M | 28 M | 20 M | ||||||
| Research Expense | 339 M | 330 M | 241 M | 160 M | 97 M | 86 M | 89 M | 90 M | 60 M | 46 M |
| Salaries And Wages | 98 M | 72 M | -10 M | -9 M | -7 M | -5 M | ||||
| Total Income Available For Interest Expense (EBIT) | -552 M | -498 M | -338 M | -186 M | -89 M | -94 M | -85 M | -111 M | 17 M | -37 M |
| Total Revenues | 18 M | 8 M | 95 M | 70 M | 56 M | 27 M | 32 M | 13 M | 106 M | 29 M |
| Total Expenses | 555 M | 504 M | 419 M | 257 M | 150 M | 126 M | -120 M | -127 M | -88 M | -66 M |
| Total Revenue | 18 M | 8 M | 95 M | 70 M | 56 M | 27 M | 32 M | 13 M | 106 M | 29 M |
| Amord | 112000.0 | 79000.0 | 66000.0 | |||||||
| Avgshs | 111979.0 | 96524.0 | 89825.0 | 76886.0 | 64524.0 | 58 M | 54 M | 49 M | 40 M | 39 M |
| Avgshsdt | 111979.0 | 96524.0 | 89825.0 | 76886.0 | 64524.0 | 58 M | 55 M | 49 M | 43 M | 39 M |
| Basiceps | -5.26 | -5.45 | -4.33 | -2.8 | -1.97 | -2.11 | -2.59 | 0.41 | -0.97 | |
| Basicepscont | -5.26 | -5.45 | -4.33 | -2.8 | -1.97 | -2.11 | ||||
| Cor | 339 M | 330 M | 241 M | 160 M | 97 M | |||||
| Depamor | 10 M | 12 M | 6 M | 2 M | 2 M | 1 M | -1 M | -2 M | -700000.0 | -600000.0 |
| Dileps | -5.26 | -5.45 | -4.33 | -2.8 | -1.97 | -2.11 | -1.95 | -2.59 | 0.39 | -0.97 |
| Dilepscont | -5.26 | -5.45 | -4.33 | |||||||
| Intinc | 11 M | 1000000.0 | 5 M | 5 M | 4 M | 3 M | 464000.0 | 174000.0 | ||
| Netincdisc | -590 M | -526 M | -389 M | -215 M | -127 M | -122 M | -106 M | -128 M | 16 M | -38 M |
| Othincexp | -53 M | -28 M | -25 M | -331000.0 | -5 M | -5 M | -100000.0 | |||
| Pretaxinc | -590 M | -497 M | -389 M | -202 M | -105 M | -101 M | -89 M | -114 M | 16 M | -38 M |
| Resdev | 339 M | 330 M | 241 M | 160 M | 97 M | 86 M | 89 M | 90 M | 60 M | 46 M |
| Sga | 215 M | 174 M | 178 M | 97 M | 53 M | 40 M | 31 M | 36 M | 28 M | 20 M |
| Shsout | 118 M | 103 M | 95 M | 85 M | 71 M | 59 M | 55 M | 54 M | 42 M | 40 M |
| Specincchg | 5 M | |||||||||
| Taxprov | -1000.0 | -1000.0 |